CD274 and neoplasm: Median overall survival observed in atezolizumab plus carboplatin/etoposide versus placebo plus carboplatin/etoposide among those with PD-L1 expression on tumor cells or tumor-infiltrating immune cells <1%, ≥1%, and ≥5% was 10.2 vs. 8.3 months (HR = 0.51, 95% CI = 0.30–0.89), 9.7 vs. 10.6 months (HR = 0.87, 95% CI = 0.51–1.49), and 21.6 vs. 9.2 months (HR = 0.60, 95% CI = 0.25–1.46).